Robert Schmidt - ADC Therapeutics Insider
| ADCT Stock | USD 2.03 0.04 2.01% |
Insider
Robert Schmidt is Vice President Corporate Controller & Chief Accounting Officer of ADC Therapeutics SA since 2020.
| Age | 43 |
| Tenure | 4 years |
| Address | BiopOle, Epalinges, Switzerland, 1066 |
| Phone | 41 21 653 02 00 |
| Web | https://www.adctherapeutics.com |
Robert Schmidt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Schmidt against ADC Therapeutics stock is an integral part of due diligence when investing in ADC Therapeutics. Robert Schmidt insider activity provides valuable insight into whether ADC Therapeutics is net buyers or sellers over its current business cycle. Note, ADC Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell ADC Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Schmidt over three months ago Acquisition by Robert Schmidt of 21858 shares of Newell Brands subject to Rule 16b-3 |
ADC Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2117) % which means that it has lost $0.2117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0553) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics' management efficiency ratios could be used to measure how well ADC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.70 in 2024, whereas Return On Tangible Assets are likely to drop (0.71) in 2024. At this time, ADC Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 457.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 48.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dana MBA | Allovir | 48 | |
| Thomas Doyle | Kura Oncology | 53 | |
| William JD | Akero Therapeutics | 51 | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Phillip Samayoa | Generation Bio Co | 37 | |
| Troy JD | Kura Oncology | 55 | |
| Michael Diem | Century Therapeutics | 53 | |
| John II | Ultragenyx | 58 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Peter Heutink | Alector | N/A | |
| Gregory Russotti | Century Therapeutics | 57 | |
| Robert Kotin | Generation Bio Co | 68 | |
| Michelle Corral | Alector | N/A | |
| Stephen MD | Kura Oncology | 52 | |
| Jaume Pons | Alx Oncology Holdings | 58 | |
| Diana MD | Allovir | 52 | |
| Shane Williams | Century Therapeutics | N/A | |
| Frank McCormick | Avidity Biosciences | 74 | |
| Prof Davis | Avidity Biosciences | N/A | |
| Agustin MD | Allovir | 60 | |
| Cameron MD | Generation Bio Co | 54 | |
Management Performance
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 |
ADC Therapeutics Leadership Team
Elected by the shareholders, the ADC Therapeutics' board of directors comprises two types of representatives: ADC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADC. The board's role is to monitor ADC Therapeutics' management team and ensure that shareholders' interests are well served. ADC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kimberly Pope, Chief Human Resource Officer, Senior Vice President | ||
| Thomas Rinderknecht, Non-Executive Independent Director | ||
| Peter Greaney, Head of Corporate Development | ||
| Lisa Skelton, Vice President - Global Project Management | ||
| Joseph Camardo, Senior Vice President Chief Medical Officer | ||
| Christopher Martin, Chief Executive Officer, Executive Director | ||
| Viviane Monges, Non-Executive Independent Director | ||
| Michael Mulkerrin, Chief Officer | ||
| Jennifer Creel, Chief Financial Officer | ||
| Mohamed MD, Chief Officer | ||
| Robert Schmidt, Vice President Corporate Controller & Chief Accounting Officer | ||
| Thomas Pfisterer, Non-Executive Independent Director | ||
| MS MBA, CEO Director | ||
| Peter Esq, Secretary Officer | ||
| Stephane Henchoz, Director of Finance | ||
| Stephen Evansfreke, Non-Executive Independent Director | ||
| Tyrell Rivers, Non-Executive Independent Director | ||
| Jennifer Herron, Senior Vice President, Chief Commercial Officer | ||
| Ron Squarer, Non-Executive Chairman of the Board | ||
| Peter Hug, Non-Executive Independent Director | ||
| Victor Sandor, Non-Executive Independent Director | ||
| Michael Forer, Vice Chairman of the Board of Directors, Executive Vice President, Chief Financial Officer | ||
| Amanda Hamilton, Investor Officer | ||
| Jose MBA, Chief Officer | ||
| Susan Romanus, Chief Compliance Officer | ||
| Jacques Theurillat, Non-Executive Independent Director | ||
| Chris Martin, Chief Executive Officer, Member of the Board of Directors | ||
| Patrick Berkel, Senior Vice President, Research & Development | ||
| Kristen HarringtonSmith, Chief Officer | ||
| Richard Onyett, Vice President - Business Development | ||
| Dr DPHIL, CoFounder Director | ||
| Eugenia Litz, Vice Communications | ||
| Peter Corr, Non-Executive Independent Director | ||
| Lisa Kallebo, Corporate Officer |
ADC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ADC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 42.69 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Shares Owned By Insiders | 21.02 % | ||||
| Shares Owned By Institutions | 61.39 % | ||||
| Number Of Shares Shorted | 3.17 M | ||||
| Price To Earning | 19.80 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.